Friday, June 29, 2018

Ixekizumab safe in patients with psoriatic arthritis

Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2, and -P3) reveals that ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study.

No comments:

Post a Comment